RBC Capital explores the implications on biotech stocks of Robert F. Kennedy Jr. potentially departing the Health and Human Services. Amid “escalating pushback,” a resignation or force out “could certainly be a possibility,” the analyst tells investors in a research note. RBC believes RFK Jr.’s departure would likely be an overall positive for the biotech sector. The move would benefit vaccine maker Moderna (MRNA), distributor of pre-exposure prophylaxis medications Gilead (GILD), and neuropsychology companies Axsome Therapeutics (AXSM), Biohaven (BHVN) and Alkermes (ALKS), contends RBC. The firm believes healthcare overall could be viewed as “less unpredictable” and “more investable” should RFK, Jr. depart his position.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Veeva receives another Top 20 Vault CRM commitment, says Raymond James
- Veeva says Gilead commits to Veeva Vault CRM
- Xilio Therapeutics announces initiation of Phase 2 trial for efarindodekin alfa
- Gilead Sciences Advances GS-4321 Study for Chronic Hepatitis Delta
- Gilead Sciences Advances Pediatric HIV Treatment with New Study Update